Ian E. Krop
Advertisement
Articles by Ian E. Krop
44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)
ByIan E. Krop,Norikazu Masuda,Toru Mukohara,Shunji Takahashi,Takahiro Nakayama,Kenichi Inoue,Hiroji Iwata,Tatsuya Toyama,Yutaka Yamamoto,Damien Hansra,Masato Takahashi,Akihiko Osaki,Kumiko Koyama,Tatsuya Inoue,Takatoshi Yonekura,Joseph Mostillo,Shoichi Ohwada,Yoshimi Tanaka,David Sternberg,Kan Yonemori
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
2
Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL
3
3 Things You Should Know About Future Directions for BsAbs and ADCs in NSCLC
4
T-DM1 Confers Lower Cardiotoxicity Risk in HER2+ Advanced Breast Cancer
5
